0.0010
0.0000
(0.00%)
May 1 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 0.00 - 0.01 |
| Open | - |
| Vol / Avg. | 0.00/4,208.00 |
| Mkt cap | 47,048.00 |
| P/E | - |
| Div/yield | - |
| EPS | -0.04 |
| Shares | 47.05M |
| Beta | 4.02 |
| Inst. own | 0% |
Key stats and ratios
| Q2 (Jun '08) | 2007 | |
| Net profit margin | - | -5179.04% |
| Operating margin | - | -5155.90% |
| EBITD margin | - | -3623.02% |
| Return on average assets | -184.03% | -103.73% |
| Return on average equity | -270.64% | -128.16% |
| Employees | 4 | - |
| Carbon Disclosure Rating | - | - |
Address
310 Authority Drive
FITCHBURG, MA 01420
United States - Map
+1-978-6960020 (Phone)
+971-978-6960026 (Fax)
FITCHBURG, MA 01420
United States - Map
+1-978-6960020 (Phone)
+971-978-6960026 (Fax)
External links
Discussion Group - Google Finance
Advertisement
Description
Integrated Pharmaceuticals, Inc. is a development-stage company. As of June 30, 2008, the Company is engaged in the development of clinically active pharmaceutical compounds, including active small molecules and recombinant deoxyribonucleic acid (DNA) technology derived products.
Officers and directors
| Peter Smith Featherston | President, Director | |
| David H. Smith II | Chief Financial Officer, Director | |
| Nilu Prasad Chatterjee Ph.D. | Vice President - Research & Development, Director | |
| Sally Johnson-Chin | Director | |
| Kenneth P. Wlosek | Director |